- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Washington, DC — New research has been released that further highlights the potential role of medical cannabis in combating the Nation’s opioid crisis . Two studies, published on April 2nd by the Journal of the American Medical Association reveal a net decrease in opioid prescriptions in states with medical cannabis laws for Medicare and Medicaid populations.
The first study, conducted by researchers at the University of Georgia, found that states with active medical cannabis dispensaries saw 3,742,000 fewer daily doses per year filled for prescription opioids under Medicare Part D (typically enrollees are over 65) compared to states without medical cannabis programs. This decrease equates to about a 14% reduction in opioid prescriptions in states with medical cannabis laws. The other study revealed that states with medical cannabis laws were associated with a 5.88% lower rate of opioid prescribing for individuals enrolled in Medicaid (typically enrollees are low income) than states without medical cannabis laws.
“This research continues to validate the notion that cannabis is an effective tool in pain management” said Steph Sherer, Executive Director for Americans for Safe Access. “The latest numbers show us that there were over 64,000 opioid deaths last year. We need to be doing more to fight this epidemic, especially by making sure that individuals suffering from chronic pain have the option to use non-addictive, effective pain treatments like medical cannabis.”
In January 2017, the National Academies of Sciences, Engineering, and Medicine found significant evidence that cannabis is effective at treating pain in some conditions. Previously published research has indicated that states with medical cannabis laws have shown up to a 25% reduction in opioid deaths and that states with medical cannabis dispensaries have shown reductions in opioid overdose deaths by as much as 40%.
In response to the ongoing opioid crisis, Americans for Safe Access, in partnership with the U.S. Pain Foundation and other advocacy organizations launched the End Pain, Not Lives campaign in late 2017. The campaign focuses on making cannabis an option for pain management.
More can be found about the campaign here.